Two new articles describe the use and implementation of monoclonal antibodies to treat COVID-19 in children. While these studies provide valuable guidance for pediatric clinicians, more studies of monoclonal antibodies and other COVID-19 therapies in children are needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jpids/piad006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study.
Headache
December 2024
Headache Unit, Neurology Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Objective: To evaluate the effectiveness of first switching between monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor in the treatment of migraine.
Background: Although mAbs targeting CGRP or its receptor have emerged as a leading treatment for migraine prevention, a proportion of patients do not respond. While switching between these antibodies is a common clinical practice in such cases, the effectiveness remains a subject of study.
A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases.
Front Immunol
December 2024
Tavotek Biotherapeutics, Inc., Lower Gwynedd Township, PA, United States.
Introduction: Thymic stromal lymphopoietin (TSLP) is a master regulator of allergic inflammation against pathogens at barrier surfaces of the lung, skin, and gut. However, aberrant TSLP activity is implicated in various allergic, chronic inflammation and autoimmune diseases and cancers. Biologics drugs neutralizing excess TSLP activity represented by tezepelumab have been approved for severe asthma and are being evaluated for the treatments of other TSLP-mediated diseases.
View Article and Find Full Text PDFImmune checkpoint inhibitor-associated diabetic ketoacidosis and insulin-dependent diabetes: a case report.
J Med Case Rep
December 2024
Emergency Medicine, Vancouver General Hospital, Vancouver, Canada.
Background: Immunotherapy, including the use of immune checkpoint inhibitors such as nivolumab, is increasingly common in cancer treatment and can lead to various immune-related adverse effects, including rare cases of diabetic ketoacidosis. This case report highlights an unique instance of nivolumab-induced diabetic ketoacidosis in a patient without prior history of diabetes, emphasizing the importance of careful monitoring even in those without traditional risk factors.
Case Presentation: We report a case of a 70-year-old Caucasian male with metastatic esophageal adenocarcinoma who developed diabetic ketoacidosis 3 weeks after stopping nivolumab therapy.
Association between quantitative CT body composition analysis and prognosis in cetuximab-based first-line treatment for advanced colorectal cancer patients.
BMC Cancer
December 2024
Department of Medical Oncology, Division of Life Sciences and Medicine, The First Affiliated Hospital of University of Science and Technology of China (USTC), University of Science and Technology of China, Anhui Provincial Cancer Hospital, Hefei, 230001, China.
Background: The objective of this study is to investigate the potential association between change in body composition before and after cetuximab-based therapy and the prognostic outcomes among individuals diagnosed with advanced colorectal cancer.
Methods: A retrospective analysis was undertaken on a cohort of 81 patients diagnosed with RAS wild-type (WT) metastatic colorectal cancer (mCRC) who were treated with cetuximab-based first-line therapy. To assess relevant body composition parameters, quantitative computed tomography (QCT) scans were conducted both before and after cetuximab treatment.
Leachables Analysis from a Closed Connected Single-Use mAb Purification Process.
PDA J Pharm Sci Technol
December 2024
Cytiva, Bjorkgatan 30, 75323 Uppsala, Sweden.
During a closed connected single-use monoclonal antibody (mAb) purification process, samples for leachables screening were gathered from two parallel processes (using different capturing chromatography), from perfusion culture to final storage bags. These samples were prepared and analyzed using screening methods for HS-GC-MS, GC-MS, LC-QToF/ESI pos and neg, to be able to identify a broad spectrum of leachables. The identified compounds were sorted into sample points from different steps of the mAb process, compared with available extractables data mapped from the process equipment used.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!